These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Regulatory T and B lymphocytes in a spontaneous autoimmune polyneuropathy. Quan S; Sheng JR; Abraham PM; Soliven B Clin Exp Immunol; 2016 Apr; 184(1):50-61. PubMed ID: 26671281 [TBL] [Abstract][Full Text] [Related]
44. Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells. Yoshizaki A; Taniguchi T; Saigusa R; Fukasawa T; Ebata S; Numajiri H; Nakamura K; Yamashita T; Takahashi T; Toyama T; Asano Y; Tedder TF; Sato S Ann Rheum Dis; 2016 Oct; 75(10):1858-65. PubMed ID: 26567180 [TBL] [Abstract][Full Text] [Related]
45. MicroRNA-30c attenuates fibrosis progression and vascular dysfunction in systemic sclerosis model mice. Kanno Y; Shu E; Niwa H; Seishima M; Ozaki KI Mol Biol Rep; 2021 Apr; 48(4):3431-3437. PubMed ID: 33913094 [TBL] [Abstract][Full Text] [Related]
46. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342 [TBL] [Abstract][Full Text] [Related]
47. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404 [TBL] [Abstract][Full Text] [Related]
48. Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis. Grönberg C; Rattik S; Tran-Manh C; Zhou X; Rius Rigau A; Li YN; Györfi AH; Dickel N; Kunz M; Kreuter A; Matei EA; Zhu H; Skoog P; Liberg D; Distler JH; Trinh-Minh T Ann Rheum Dis; 2024 Aug; 83(9):1156-1168. PubMed ID: 38594058 [TBL] [Abstract][Full Text] [Related]
49. Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice. Taniguchi T; Asano Y; Akamata K; Noda S; Takahashi T; Ichimura Y; Toyama T; Trojanowska M; Sato S Arthritis Rheumatol; 2015 Feb; 67(2):517-26. PubMed ID: 25385187 [TBL] [Abstract][Full Text] [Related]
50. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Brkic Z; van Bon L; Cossu M; van Helden-Meeuwsen CG; Vonk MC; Knaapen H; van den Berg W; Dalm VA; Van Daele PL; Severino A; Maria NI; Guillen S; Dik WA; Beretta L; Versnel MA; Radstake T Ann Rheum Dis; 2016 Aug; 75(8):1567-73. PubMed ID: 26371289 [TBL] [Abstract][Full Text] [Related]
51. alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma? Kokot A; Sindrilaru A; Schiller M; Sunderkötter C; Kerkhoff C; Eckes B; Scharffetter-Kochanek K; Luger TA; Böhm M Arthritis Rheum; 2009 Feb; 60(2):592-603. PubMed ID: 19180474 [TBL] [Abstract][Full Text] [Related]